Market Overview

Takeda, Lundbeck Announce FDA Approval of Brintellix for Treatment of Adults with MDD

Share:
Related TKPYY
Exclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride
Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable

Takeda Pharmaceutical Company Limited (OTC: TKPYY) and H. Lundbeck A/S (OTC: HLUKF) jointly announced Monday that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year.1 The mechanism of the antidepressant effect of Brintellix is not fully understood. It is an inhibitor of serotonin (5-HT) reuptake and that is thought to be a mechanism of its action.  It is also an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3, 5-HT1D and 5-HT7 receptors. The contribution of each of these activities to Brintellix's antidepressant effect has not been established. It is considered to be the first and only compound with this combination of pharmacodynamic activity. The clinical relevance of this is unknown.

"MDD is a multifaceted disorder that encompasses emotional, physical and cognitive symptoms that may make it challenging to treat," said Michael Thase, M.D., professor of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. "Because patients respond to treatments differently, it is important to have additional new

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (TKPYY + HLUKF)

View Comments and Join the Discussion!